NeuroPace Issues 2025 Financial Guidance Targets
NeuroPace (NPCE) has announced its 2025 financial guidance and three-year strategic objectives. The company projects 2025 revenue between $92-96 million, representing 15.5-20.5% growth from 2024's expected range of $79.4-79.9 million. The gross margin target is set at 73-75%, with total operating expenses projected at $92-95 million, including $11 million in stock-based compensation.
The company's three-year strategic plan aims to establish NeuroPace as the leader in drug-resistant epilepsy therapy, targeting a 20%+ revenue CAGR. Key objectives include expanding indications to Idiopathic Generalized and Pediatric drug-resistant epilepsy patients, advancing AI tools and remote programming capabilities, enhancing patient awareness through direct-to-consumer campaigns, and achieving cash flow breakeven.
NeuroPace (NPCE) ha annunciato le sue previsioni finanziarie per il 2025 e i suoi obiettivi strategici triennali. L'azienda prevede un fatturato per il 2025 compreso tra i 92 e i 96 milioni di dollari, rappresentando una crescita del 15,5-20,5% rispetto all'intervallo previsto per il 2024, pari a 79,4-79,9 milioni di dollari. L'obiettivo di margine lordo è fissato tra 73% e 75%, con spese operative totali proiettate tra 92 e 95 milioni di dollari, inclusi 11 milioni di dollari in compensi azionari.
Il piano strategico triennale dell'azienda mira a stabilire NeuroPace come leader nella terapia per l'epilessia resistente ai farmaci, puntando a un CAGR del fatturato superiore al 20%. Tra gli obiettivi chiave ci sono l'espansione delle indicazioni ai pazienti pediatrici e all'epilessia generalizzata idiopatica resistente ai farmaci, il progresso degli strumenti di intelligenza artificiale e delle capacità di programmazione remota, l'aumento della consapevolezza dei pazienti attraverso campagne dirette ai consumatori, e il raggiungimento del pareggio di flussi di cassa.
NeuroPace (NPCE) ha anunciado su guía financiera para 2025 y sus objetivos estratégicos a tres años. La compañía proyecta ingresos de 2025 entre $92 y $96 millones, lo que representa un crecimiento del 15.5-20.5% en comparación con el rango esperado de 2024 de $79.4-79.9 millones. El objetivo de margen bruto se establece entre 73-75%, con gastos operativos totales proyectados entre $92 y $95 millones, incluidos $11 millones en compensación basada en acciones.
El plan estratégico a tres años de la compañía tiene como objetivo establecer a NeuroPace como el líder en terapia para la epilepsia resistente a medicamentos, con un objetivo de CAGR de ingresos superior al 20%. Los objetivos clave incluyen expandir las indicaciones a pacientes con epilepsia resistente a medicamentos idiopática generalizada y pediátrica, avanzar en herramientas de inteligencia artificial y capacidades de programación remota, aumentar la conciencia de los pacientes a través de campañas directas al consumidor y alcanzar el equilibrio de flujo de caja.
NeuroPace (NPCE)는 2025년 재무 지침과 3개년 전략 목표를 발표했습니다. 회사는 2025년 매출을 9천2백만에서 9천6백만 달러로 예상하며, 이는 2024년 예상 범위인 7천9백4십만에서 7천9백9십만 달러 대비 15.5-20.5% 성장에 해당합니다. 매출 총 이익 목표는 73-75%로 설정되었으며, 총 운영비용은 9천2백만에서 9천5백만 달러로 예상하고 있습니다. 이 금액에는 1천1백만 달러의 주식 기반 보상이 포함됩니다.
회사의 3개년 전략 계획은 약물 저항성 간질 치료의 선두주자로 NeuroPace를 설립하는 것을 목표로 하며, 20% 이상의 매출 CAGR을 목표로 하고 있습니다. 주요 목표에는 특발성 전신성 및 소아 약물 저항성 간질 환자에 대한 적응증 확대, 인공지능 도구 및 원격 프로그래밍 능력 발전, 소비자 직접 캠페인을 통한 환자 인식 강화, 현금 흐름 손익 분기점 도달 등이 포함됩니다.
NeuroPace (NPCE) a annoncé ses prévisions financières pour 2025 et ses objectifs stratégiques sur trois ans. L'entreprise projette un chiffre d'affaires pour 2025 compris entre 92 et 96 millions de dollars, représentant une croissance de 15,5 à 20,5 % par rapport à la plage prévue pour 2024, qui est de 79,4 à 79,9 millions de dollars. L'objectif de marge brute est fixé entre 73 % et 75 %, avec des dépenses d'exploitation totales prévues entre 92 et 95 millions de dollars, y compris 11 millions de dollars en compensation basée sur des actions.
Le plan stratégique triennal de l'entreprise vise à établir NeuroPace comme le leader dans le traitement de l'épilepsie résistante aux médicaments, visant un CAGR de revenu supérieur à 20 %. Parmi les objectifs clés figurent l'élargissement des indications aux patients atteints d'épilepsie générale idiopathique et pédiatrique résistante aux médicaments, l'avancement des outils d'IA et des capacités de programmation à distance, l'amélioration de la sensibilisation des patients par le biais de campagnes de marketing direct et l'atteinte de l'équilibre des flux de trésorerie.
NeuroPace (NPCE) hat seine Finanzprognose für 2025 und seine dreijährigen strategischen Ziele bekannt gegeben. Das Unternehmen rechnet mit Umsätzen von 2025 zwischen 92 und 96 Millionen US-Dollar, was einem Wachstum von 15,5-20,5% im Vergleich zum voraussichtlichen Bereich von 79,4-79,9 Millionen US-Dollar im Jahr 2024 entspricht. Das Ziel für die Bruttomarge liegt bei 73-75%, die Gesamtausgaben sind auf 92-95 Millionen US-Dollar prognostiziert, einschließlich 11 Millionen US-Dollar an aktienbasierter Vergütung.
Der dreijährige strategische Plan des Unternehmens hat das Ziel, NeuroPace als führenden Anbieter in der Therapie von medikamentenresistenter Epilepsie zu etablieren, mit einem Ziel von mehr als 20% Umsatz-CAGR. Zu den Schlüsselzielen gehören die Erweiterung der Indikationen für Patienten mit idiopathischer generalisierter und pädiatrischer medikamentenresistenter Epilepsie, der Fortschritt bei KI-Tools und der Remote-Programmierbarkeit, die Steigerung des Patientenbewusstseins durch direkte Verbraucherkampagnen und das Erreichen eines Cashflow-Break-Even.
- Projected revenue growth of 15.5-20.5% for 2025
- Strong gross margin target of 73-75%
- Targeted 20%+ three-year revenue CAGR
- Strategic plan for indication expansion to new patient segments
- Path to cash flow breakeven outlined
- Operating expenses projected at $92-95 million, nearly equal to revenue
- Significant stock-based compensation expense of $11 million
Insights
NeuroPace's 2025 guidance presents a compelling growth trajectory in the neuromodulation market. The targeted revenue range of
The planned operating expenses of
Three key strategic elements stand out:
- The indication expansion into Idiopathic Generalized and Pediatric drug-resistant epilepsy could substantially expand the addressable market
- The focus on AI Tools and Remote Programming positions NeuroPace at the forefront of neuromodulation technology, potentially creating competitive barriers
- The emphasis on direct-to-consumer campaigns and Project CARE addresses the critical challenge of patient awareness and access in the medical device sector
The commitment to achieving cash flow breakeven within three years while maintaining
– 2025 revenue guidance of
– 2025 gross margin guidance of
– Three-year targets of
MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually here, and the accompanying slide presentation can be accessed here).
2025 Financial Guidance and Three-Year Strategic Objectives
NeuroPace provided initial financial guidance targets for 2025:
- Revenue of
$92 million –$96 million , representing growth of15.5% –20.5% versus the midpoint of the expected 2024 revenue range of$79.4 million –$79.9 million - Gross margin of
73% –75% - Total operating expenses of
$92 million –$95 million , including approximately$11 million in stock-based compensation
Management also outlined its long-range plan of becoming the recognized leader in drug-resistant epilepsy therapy and fully develop the potential of the RNS System. To this end, the Company is focused on achieving the following three-year strategic objectives:
20% + revenue CAGR- Indication expansion to include Idiopathic Generalized and Pediatric drug-resistant epilepsy patients
- Become the neuromodulation category leader in efficiency and ease of use with AI Tools and Remote Programming
- Significantly expand patient and referral awareness and access through direct-to-consumer campaigns and Project CARE
- Achieve cash flow break even
Event Webcast
A replay of the event webcast can be accessed here, and the accompanying slide presentation can be accessed here.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace’s anticipated revenue, gross margin and operating expenses for the year ending 2025; and NeuroPace’s three-year strategic objectives and the Company’s ability to achieve these objectives on the expected timelines. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: actual operating results may differ significantly from any guidance provided; uncertainties related to market acceptance and adoption of NeuroPace’s RNS System and impacts to NeuroPace’s revenue for 2025 and in the future; risks that NeuroPace’s operating expenses could be higher than anticipated and that the Company’s gross margin may be lower than forecast; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System; risks related to product development; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
What is NeuroPace's (NPCE) projected revenue for 2025?
What is NPCE's targeted gross margin for 2025?
What are NPCE's projected operating expenses for 2025?
What is NeuroPace's targeted revenue CAGR for the next three years?
When does NPCE expect to achieve cash flow breakeven?
